Affiliation:
1. Clinical Hospital No. 122 of the North- Western District Scientific and Clinical Center named after L.G. Sokolov; St Petersburg State University
2. St Petersburg State University
3. GrandMed Surgery
Abstract
Currently pulmonary embolism (PE) is already on the 3rd place in terms of the frequency of occurrence among vascular diseases, and there is a global trend towards an increase in its frequency. PE is also considered as the most common cause of preventable death in the hospital. In the countries of Europe, Asia and the USA, there is a tendency to reduce the cases of fatal PE due to the use of more effective conservative therapy, invasive interventions and following the Recommendations. Since 2019, the European Guidelines for the diagnosis and treatment of PE have made the use of direct oral anticoagulants preferable in comparison with oral vitamin K antagonists.A case of massive PE in a 42-year-old patient developed in the specialized department of the hospital shortly after being transferred from the intensive care unit with verified PE of small branches (D-dimer, lung scintigraphy, Echo-cardiography) is presented. The debut of a massive PE in the form of a syncopal state with cardiogenic shock, required an urgent transfer of the patient to artificial lung ventilation, the use of vasopressors and systemic thrombolysis. During Echo-cardiography, a mobile blood clot was located in the right atrium. An emergency thrombectomy was performed from the pulmonary trunk and pulmonary arteries in conditions of artificial blood circulation, later a cava filter was installed. The features of anamnesis characteristic of PE (hormonal contraceptives), complaints (sudden shortness of breath, heaviness behind the sternum at admission) and concomitant pathology (drug-induced thyrotoxicosis) are analyzed.The results of the subsequent 8-year follow-up without relapses of PE are considered, the feature of which was the use of Rivaroxaban as an anticoagulant and angiovit (B vitamins – 6, 9 and 12) for the correction of hereditary hyperhomocysteinemia. Risk factors and modern standards of treatment of massive PE in the acute period and in the long term are discussed.
Reference29 articles.
1. Konstantinides S.V., Meyer G., Becattini C., Bueno H., Geersing G.J., Harjola V.P. еt al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Respiratory J. 2020;41(4):543–603. https://doi.org/10.1183/13993003.01647-2019.
2. Kearon C., Akl E.A., Ornelas J., Blaivas A., Jimenez D., Bounameaux H. et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315–352. https://doi.org/10.1016/j.chest.2015.11.026.
3. Lobastov K.V. Modern approaches to determining the duration of anticoagulant therapy for venous thromboembolic complication Khirurgiya. Zhurnal im. N.I. Pirogova = Pirogov Russian Journal of Surgery. 2019;(5):94–103. (In Russ.) https://doi.org/10.17116/hirurgia201905194.
4. Konstantinides S.V., Torbicki A. Agnelli G., Danchin N., Fitzmaurice D., Galiè N. et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) endorsed by the European Respiratory Society (ERS). Eur Heart J. 2014;35:3033–3069. https://doi.org/10.1093/eurheartj/ehu283.
5. Soboleva E.V. Homocysteinemia as a target of therapeutic effect in patients with coronary heart disease. Effects of simvastatin. RMZh = RMJ. 2007;(2):58–63. (In Russ.) Available at: https://www.rmj.ru/articles/kardiologiya/Gomocisteinemiya_kak_misheny_terapevticheskogo_vozdeystviya_u_ bolynyh_ishemicheskoy_boleznyyu_serdca_Effekty_simvastatina/.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献